Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Earnings Analysis: Huntsman Corp. (NYSE: HUN)

Earnings Analysis: Huntsman Corp. (NYSE: HUN)Huntsman Corporation (NYSE:HUN) recently reported its preliminary financial results based on which we provide a unique peer-based analysis of the company. Our analysis is based on the company’s performance over the last twelve months (unless stated otherwise). For a more detailed analysis of this company (and over 40,000 other global equities) please visit www.capitalcube.com.

Huntsman Corp.’s analysis versus peers uses the following peer-set: The Dow Chemical Company (NYSE:DOW), Eastman Chemical Company (NYSE:EMN), Ashland Inc. (NYSE:ASH), Rockwood Holdings, Inc. (NYSE:ROC), Cytec Industries Inc (NYSE:CYT), PolyOne Corporation (NYSE:POL) and Kronos Worldwide, Inc. (NYSE:KRO). The table below shows the preliminary results along with the recent trend for revenues, net income and returns.

Quarterly (USD million) 2012-09-30 2012-06-30 2012-03-31 2011-12-31 2011-09-30
Revenues 2,741.0 2,914.0 2,913.0 2,632.0 2,976.0
Revenue Growth % (5.9) 0.0 10.7 (11.6) 1.4
Net Income 116.0 126.0 167.0 99.0 (44.0)
Net Income Growth % (7.9) (24.6) 68.7 N/A (138.6)
Net Margin % 4.2 4.3 5.7 3.8 (1.5)
ROE % (Annualized) 22.6 26.6 37.5 22.9 (9.0)
ROA % (Annualized) 5.3 5.7 7.6 4.5 (1.9)

Valuation Drivers

Huntsman Corp.’s current Price/Book of 1.7 is about median in its peer group. We classify HUN-US as Harvesting because of the market’s low expectations of growth (PE of 7.4 compared to peer median of 18.8) despite its relatively high returns (ROE of 25.3% compared to the peer median ROE of 18.5%).

The company’s median net profit margins of 4.5% and relative asset efficiency (asset turns of 1.2x compared to peer median of 0.8x) give it some operating leverage. HUN-US’s net margin continues to trend upward and is now over one standard deviation above its five-year average net margin of 1.7%.

Economic Moat

HUN-US’s return on assets currently is around peer median (5.7% vs. peer median 4.9%) — similar to its returns over the past five years (2.1% vs. peer median 2.0%). This performance suggests that the company has no specific competitive advantages relative to its peers.

The company’s comparatively low gross margins of 21.8% versus peer median of 28.7% suggests that it has a non-differentiated strategy or is in a pricing constrained position. However, HUN-US’s pre-tax margin of 6.1% is around the peer median which, when combined with the gross margin, suggests lower operating costs relative to peers.

Growth & Investment Strategy

While HUN-US’s revenues growth has been above the peer median (3.2% vs. 1.8% respectively for the past three years), the stock’s PE ratio of 7.4 is less than the peer median. This implies that the company’s earnings are peaking and the market expects a decline in its growth expectations.

HUN-US’s annualized rate of change in capital of 0.7% over the past three years is less than its peer median of 7.6%. This below median investment level has also generated a less than peer median return on capital of 2.0% averaged over the same three years. This outcome suggests that the company has invested capital relatively poorly and now may be in maintenance mode.

Earnings Quality

HUN-US’s net income margin for the last twelve months is around the peer median (4.5% vs. peer median of 5.1%). This average margin combined with a level of accruals that is around peer median (3.5% vs. peer median of 3.1%) suggests there possibly isn’t too much accrual movement flowing into the company’s reported earnings.

HUN-US’s accruals over the last twelve months are positive suggesting a buildup of reserves. However, this level of accruals is also around the peer median and suggests the company is recording a proper level of reserves compared to its peers.

Trend Charts

Graph of Revenues Trend for Huntsman Corp. (NYSE: HUN)
Graph of Revenues Trend for Huntsman Corp. (NYSE: HUN)
Graph of Net Margin Trend for Huntsman Corp. (NYSE: HUN)
Graph of Net Margin Trend for Huntsman Corp. (NYSE: HUN)
Graph of Accruals Trend (% revenues, Quarterly) for Huntsman Corp. (NYSE: HUN)
Graph of Accruals Trend (% revenues, Annual or TTM) for Huntsman Corp. (NYSE: HUN)

Company Profile

Huntsman Corp. is a global manufacturer of differentiated organic and inorganic chemical products. The company’s products comprises of chemicals and formulations, which it markets to a diversified group of consumer and industrial customers. Its products are used in a wide range of applications which include adhesives, aerospace, automotive, construction products, durable and non-durable consumer products, electronics, medical, packaging, paints and coatings, power generation, refining, synthetic fiber, textile chemicals and dye industries. The company operates its business through five segments: Polyurethanes, Performance Products, Advanced Materials, Textile Effects and Pigments. The Polyurethanes segment manufactures and markets a broad range of polyurethane chemicals, including MDI products, PO, polyols, PG and TPU. The Performance Products segment is organized around three market areas: performance specialties, performance intermediates and maleic anhydride and licensing, and serves a wide variety of consumer and industrial end markets. The Advanced Materials segment manufactures and markets technologically advanced epoxy, acrylic and polyurethane-based polymer products. The Textile Effects segment provides market share for textile chemicals and dyes. The Pigments segment manufactures and markets titanium dioxide, which is a white pigment used to impart whiteness, brightness and opacity to products such as paints, plastics, paper, printing inks, fibers and ceramics. Huntsman was founded on October 19, 2004 and is headquartered in Salt Lake City, UT.

Disclaimer

The information presented in this report has been obtained from sources deemed to be reliable, but AnalytixInsight does not make any representation about the accuracy, completeness, or timeliness of this information. This report was produced by AnalytixInsight for informational purposes only and nothing contained herein should be construed as an offer to buy or sell or as a solicitation of an offer to buy or sell any security or derivative instrument. This report is current only as of the date that it was published and the opinions, estimates, ratings and other information may change without notice or publication. Past performance is no guarantee of future results. Prior to making an investment or other financial decision, please consult with your financial, legal and tax advisors. AnalytixInsight shall not be liable for any party’s use of this report. AnalytixInsight is not a broker-dealer and does not buy, sell, maintain a position, or make a market in any security referred to herein. One of the principal tenets for us at AnalytixInsight is that the best person to handle your finances is you. By your use of our services or by reading any our reports, you’re agreeing that you bear responsibility for your own investment research and investment decisions. You also agree that AnalytixInsight, its directors, its employees, and its agents will not be liable for any investment decision made or action taken by you and others based on news, information, opinion, or any other material generated by us and/or published through our services. For a complete copy of our disclaimer, please visit our website www.analytixinsight.com.
This article was originally written by abha.dawesar, and posted on CapitalCube.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!